
Quarterly ResultNov 13, 2026, 08:06 AM
Fortress Biotech Q3 Revenue Up 9% to $19.2M; Repays Debt
AI Summary
Fortress Biotech announced its third quarter 2026 financial results, reporting a 9% increase in net revenue to $19.2 million. The company also highlighted significant corporate developments, including the full repayment of its credit facility, leaving no outstanding debt at the parent level. Key strategic updates include the in-licensing of FB-607 for IBS-D, advancements in partnered programs like Crystalys Therapeutics' $130 million Series B financing, and the Japanese approval of anselamimab. While revenue increased, the company reported a net loss attributable to common stockholders of $(7.9) million for the quarter.
Key Highlights
- Fortress Biotech reported Q3 2026 net revenue of $19.2 million, a 9% increase year-over-year.
- The company repaid its $15.0 million credit facility in full in September 2026, eliminating parent-level debt.
- A subsidiary licensed FB-607 for IBS-D, currently in Phase 2 trials with data expected in H2 2027.
- Journey Medical's Emrosi® generated approximately 40,000 prescriptions in Q3 2026.
- Crystalys Therapeutics closed a $130 million Series B financing for dotinurad development.
- Anselamimab was approved in Japan for systemic kappa light chain amyloidosis in September 2026.
- Consolidated cash and cash equivalents increased to $152.2 million as of September 30, 2026.
- Net loss attributable to common stockholders was $(7.9) million, or $(0.23) per share, for Q3 2026.
Price Impact
More from FBIO